Remove 2030 Remove Drug Research Remove Therapies
article thumbnail

Distinguishing the Roles of Preclinical vs. Clinical CROs in Clinical Research

Vial

In this article, we will define preclinical and clinical CROs, as well as highlight the unique needs and challenges of these organizations in their respective stages of drug research. billion by 2030 at a compound annual growth rate (CAGR) of 7.5% between 2024 and 2030. between 2024 and 2030. over this period.

article thumbnail

World Malaria Day 2021

The Pharma Data

In 1999, Novartis launched the first fixed-dose Artemisinin-based Combination Therapy (ACT) and in 2009, the first dispersible pediatric ACT developed in partnership with Medicines for Malaria Venture (MMV). Follow us on social media at #MalariaFuture. The EDCTP grant of EUR 21.9 Video of No one should die of malaria. Read the reports.